Passion and purpose to transform patient journeys in anxiety and depression.

Ann Cunningham, MBA, joined our Board in January 2019. Ms. Cunningham brings over 25 years of commercial experience in the pharmaceutical industry. She is the Founder and Chief Executive Officer of i³ Strategy Partners, a pharmaceutical consulting group, and served as Vistagen’s Chief Commercial Officer in 2021-2022. Ms. Cunningham has guided senior pharmaceutical and biotechnology executives in planning and executing multiple successful pharmaceutical portfolio strategies and blockbuster brand launches, including instrumental roles in the successful commercial launch and sales of Lilly’s Cymbalta®, for which she led the development and execution of the “Depression Hurts” consumer campaign, and Otsuka America’s Rexulti®, serving as Senior Director, Global Brand Lead. While at Lilly, she also led psychiatry sales teams as Area Sales Director responsible for Cymbalta®, Zyprexa® and Strattera®. Ms. Cunningham also led the commercial development of a product portfolio as Vice President of Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical Industries. Ms. Cunningham holds a B.A. in Psychology from Yale University and an MBA from the University of Michigan, Stephen M. Ross School of Business.